DiaMedica Therapeutics Inc. Common Stock

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell DMAC and other ETFs, options, and stocks.

About DMAC

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). 

CEO
Rick John Pauls
CEORick John Pauls
Employees
28
Employees28
Headquarters
Minneapolis, Minnesota
HeadquartersMinneapolis, Minnesota
Founded
2000
Founded2000
Employees
28
Employees28

DMAC Key Statistics

Market cap
156.95M
Market cap156.95M
Price-Earnings ratio
-5.65
Price-Earnings ratio-5.65
Dividend yield
Dividend yield
Average volume
113.39K
Average volume113.39K
High today
$3.94
High today$3.94
Low today
$3.65
Low today$3.65
Open price
$3.85
Open price$3.85
Volume
112.43K
Volume112.43K
52 Week high
$6.82
52 Week high$6.82
52 Week low
$2.14
52 Week low$2.14

DMAC News

Simply Wall St 2h
DiaMedica Therapeutics Insiders Up US$4.1m On US$9.00m Investment

DiaMedica Therapeutics Inc. ( ) insiders who acquired shares over the previous 12 months, can probably afford to ignore the recent 12% decline in the stock pric...

DiaMedica Therapeutics Insiders Up US$4.1m On US$9.00m Investment

People also own

Based on the portfolios of people who own DMAC. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.